Pacific Edge Ltd
NZX:PEB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Pacific Edge Ltd
NZX:PEB
|
NZ |
|
Nippon Sanso Holdings Corp
TSE:4091
|
JP |
|
Xiamen Kingdomway Group Co
SZSE:002626
|
CN |
|
Japan Hospice Holdings Inc
TSE:7061
|
JP |
|
Evs Broadcast Equipment SA
XBRU:EVS
|
BE |
|
P
|
Petrovietnam Packaging JSC
VN:PBP
|
VN |
|
Gajah Tunggal Tbk PT
IDX:GJTL
|
ID |
|
W
|
Win Hanverky Holdings Ltd
HKEX:3322
|
HK |
|
Grupo Gigante SAB de CV
BMV:GIGANTE
|
MX |
|
M
|
Mdwerks Inc
OTC:MDWK
|
US |
|
Garbi Finvest Ltd
BSE:539492
|
IN |
|
S
|
Sky Quarry Inc
NASDAQ:SKYQ
|
US |
|
Organto Foods Inc
XTSX:OGO
|
CA |
|
BIOLASE Inc
OTC:BIOLQ
|
US |
|
Fiducial Real Estate SA
PAR:ORIA
|
FR |
Pacific Edge Ltd
Pacific Edge Ltd. engages in the discovery and commercialization of diagnostic and prognostic technology for the early detection and monitoring of cancer. The firm develops and commercializes diagnostic and prognostic tools for the early detection and management of cancers. The firm's segments include NZ Laboratory, US Laboratory and Research NZ & Australia. Its segments are engaged in the research and development of diagnostic and prognostic products for human cancer both in New Zealand and Australia, and operation of the laboratories used for the detection of bladder cancer in the United States and New Zealand. The company offers Cxbladder, which is a suite of non-invasive laboratory tests for the detection and the management of bladder cancer. Cxbladder includes a suite of urine-based molecular tests to determine the likelihood of bladder cancer in patients presenting with hematuria. Its pipeline includes Cxcolorectal, which is a prognostic gene signature for patients diagnosed with stage II or stage III colorectal cancer, enabling prediction of aggressiveness of the tumor.
Pacific Edge Ltd. engages in the discovery and commercialization of diagnostic and prognostic technology for the early detection and monitoring of cancer. The firm develops and commercializes diagnostic and prognostic tools for the early detection and management of cancers. The firm's segments include NZ Laboratory, US Laboratory and Research NZ & Australia. Its segments are engaged in the research and development of diagnostic and prognostic products for human cancer both in New Zealand and Australia, and operation of the laboratories used for the detection of bladder cancer in the United States and New Zealand. The company offers Cxbladder, which is a suite of non-invasive laboratory tests for the detection and the management of bladder cancer. Cxbladder includes a suite of urine-based molecular tests to determine the likelihood of bladder cancer in patients presenting with hematuria. Its pipeline includes Cxcolorectal, which is a prognostic gene signature for patients diagnosed with stage II or stage III colorectal cancer, enabling prediction of aggressiveness of the tumor.
